GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

GSKs Nucala (mepolizumab) Gets the United States FDAs Approval for the Treatment of Persistent Rhinosinusitis with Nasal Polyps


The approval is based upon data from the SYNAPSE study examining mepolizumab vs PBO in ~ 400 patients with CRSwNP who had a history of prior surgical treatment & & require even more surgical treatment due to extreme symptoms & & increased size of polyps
The results revealed a 57% decrease in the size of nasal polyps & & nasal blockage in patients who had surgery whereas the percentage of clients requiring systemic corticosteroid use through 52 wks. of the treatment period was lower who received the treatment
Mepolizumab is the 1st anti-IL-5 biologic to be authorized for CRSwNP & & marks the 4th indicator for eosinophil-driven illness in the US

Click here to check out complete news release/ article|Ref: Businesswire|Image: Fierce Pharma

Post Views: